7-Hydroxyflavanone

7-Hydroxyflavanone

SCHEMBL126599

O=C1C[C@H](c2ccccc2)Oc2cc(O)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 1.00
CYP19A1 P11511 7/20 1.00
MAOA P21397 1/20 1.00
PSMB5 P28074 1/20 1.00
TUBB4A P04350 1/20 0.86
TUBB P07437 1/20 0.86
YES1 P07947 1/20 0.86
TUBA3C P0DPH7 1/20 0.86
TUBA1B P68363 1/20 0.86
TUBA4A P68366 1/20 0.86
TUBB4B P68371 1/20 0.86
TUBB3 Q13509 1/20 0.86
TUBB2A Q13885 1/20 0.86
TUBB8 Q3ZCM7 1/20 0.86
TUBA3E Q6PEY2 1/20 0.86
TUBA1A Q71U36 1/20 0.86
ESR2 Q92731 1/20 0.86
TUBA1C Q9BQE3 1/20 0.86
TUBB6 Q9BUF5 1/20 0.86
TUBB2B Q9BVA1 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
7-Hydroxyflavanone SCHEMBL29843931 1.00 MAOB (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
7-Hydroxyflavanone SCHEMBL1072683 1.00 MAOB (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
7-Hydroxyflavanone SCHEMBL130266 1.00 MAOB (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL3120177 0.93 MAOB (0.87) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL1071066 0.92 CYP19A1 (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL26970367 0.92 CYP19A1 (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL74552 0.92 CYP19A1 (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL29552383 0.92 CYP19A1 (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL30352791 0.92 CYP19A1 (1.00) MAOBCYP19A1MAOAPSMB5TUBB4A
Liquirtigenin SCHEMBL4649862 0.91 CYP19A1 (0.97) MAOBCYP19A1MAOAPSMB5TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117338835-A Preparation method of medicine tablet for treating osteoporosis 广西十万山制药有限公司 2024-01-05 CN claimed
US-20260033492-A1 Pest Repellents and Uses Thereof SENSORYGEN INC (US) 2026-02-05 US disclosed
CN-120078040-A Preparation method of corn flour for corn cauterization production 巢湖美维食品有限公司 2025-06-03 CN disclosed
US-12280129-B2 Compositions and methods for improved skin care PINSKY MARK A (US) 2025-04-22 US disclosed
US-12156832-B2 Method, and system for multi-layer cosmetic pads and use thereof ELC MANAGEMENT LLC (US) 2024-12-03 US disclosed
CN-118496516-B Dichlorobenzene bisureido-beta-cyclodextrin stationary phase and preparation method and application thereof 南昌大学 2024-09-20 CN disclosed
CN-118496516-A Dichlorobenzene bisureido-beta-cyclodextrin stationary phase and preparation method and application thereof 南昌大学 2024-08-16 CN disclosed
CN-117338835-A Preparation method of medicine tablet for treating osteoporosis 广西十万山制药有限公司 2024-01-05 CN disclosed
CN-115569643-B Method for preparing chiral separation material by vacuum-assisted solid phase reaction bonding 宁波大学 2023-10-03 CN disclosed
US-20230292754-A1 Pest Repellents and Uses Thereof UNIVERSITY OF CALIFORNIA RIVERSIDE 2023-09-21 US disclosed
WO-2000062745-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062743-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062742-A2 METHODS FOR REGULATING THE CONDITION OF MAMMALIAN KERATINOUS TISSUE THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062740-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062741-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062744-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
US-6093411-A AN EMULSION COMPRISING FLAVONOIDS FOR PREVENTING OR TREATING SKIN DISORDERS THE PROCTER & GAMBLE COMPANY (US) 2000-07-25 US disclosed
US-6051602-A METHODS FOR PREVENTION OR TREATING SKIN DISORDERS USING FLAVONOID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2000-04-18 US disclosed
WO-1999047118-A1 COMPOSITIONS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed
WO-1999047113-A1 COMPOSITIONS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260033492-A1 Pest Repellents and Uses Thereof F3, TFPI, FLI1 MAOB 1790/4885CYP19A1 2958/4885MAOA 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.